Baird raised the firm’s price target on AdaptHealth (AHCO) to $16 from $14 and keeps an Outperform rating on the shares. The firm said they posted good Q4 results and a positive 2025 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO:
- AdaptHealth’s Promising Growth: Strong Q4 Results and Strategic Changes Justify Buy Rating
- AdaptHealth price target raised to $14 from $11 at RBC Capital
- AdaptHealth price target raised to $14 from $13 at Canaccord
- AdaptHealth Corp. Reports 2024 Financial Results and 2025 Outlook
- Unusually active option classes on open February 25th